---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073689"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:31:20.246290+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q4: cash $205M, OpEx down 30%, FT819 outpatient treatment milestone

## Summary
- Cash and investments $205.1M as of Dec 31, 2025; operating runway through year-end 2027.
- Q4 revenue $1.4M from Ono collaboration; total operating expenses $36.1M (R&D $25.4M, G&A $10.7M).
- FT819 off-the-shelf CAR T: 15 SLE, 4 SSc, 1 IIM patients treated; outpatient same-day discharge achieved.
- FT836 (Sword & Shield) in CRC: first patient shows >50% CEA reduction and tumor shrinkage at DL1 without conditioning chemo.
- Operating expenses reduced 30% in 2025 vs 2024; common shares 115.4M, pre-funded warrants 3.9M, preferred 2.8M.

## SEC filing metadata
- accession: 0001193125-26-073689
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312526073689/0001193125-26-073689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312526073689/fate-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073689
- JSON: https://secwatch.observer/filing/0001193125-26-073689.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.